Absci

Absci Founder and CEO Sean McClain has had a front-row seat driving the transformation of biotech. In his latest TEDx talk, Sean breaks down how the intersection of AI and biology is shifting human health and revolutionizing how science tackles disease treatment. "I thought the big idea was AI drug discovery, and that's really impactful. But as we dug deeper, we actually saw something extraordinary—that there was even a bigger idea out there. We look at diseases through the lens of chemical imbalance, biological pathways that can be turned on and off, but if you look through a slightly different lens—a physics-based lens, a first-principles lens—you actually realize that most diseases trace back to energy and balances." Watch the full talk, 'Can We Flip the Body's Regenerative Switch?', to explore Sean’s bold vision and see how Absci harnesses generative AI to engineer the future of regenerative biology. 📌Full video: https://lnkd.in/ez38WpZq

Absci is pleased to welcome Dr. Axel Haupt to our Endometriosis Advisory Board. As SVP of Clinical Investigation, Diabetes, Obesity & Complications at Eli Lilly and Company, Dr. Haupt brings deep clinical expertise that will strengthen our mission to advance ABS-201 for patients living with endometriosis.

🎧 Listen to our latest podcast feature In a true full-circle moment, our Founder and CEO, Sean McClain, returned to the University of Arizona to sit down with his former professor, Dean John Pollard, on the university’s It's an Honor Podcast. Dr. Pollard’s Chemical Thinking course was a pivotal turning point for Sean. It was the moment he realized biology wasn't just cells or molecules, but a system: a code that could be rewritten and debugged. That spark set off a journey from a curious undergraduate, to founder and CEO of Absci—a clinical-stage biopharmaceutical advancing innovative therapeutics with generative AI. It’s an inspiring conversation on leading with curiosity, how foundational mentorships shape long-term success, and the grit it takes to transform the intersection of tech and biology. Thank you for having us, Dean Pollard and the W.A. Franke Honors College – University of Arizona team! Full episode "Generative AI and Leading with Curiosity" • Apple Podcasts: https://lnkd.in/gg_XThci • Spotify: https://lnkd.in/eKHZ3Amu

Our Phase 1/2a HEADLINE clinical trial is well underway in Australia and progressing for androgenetic alopecia (also known as male and female pattern hair loss). Our trial was recently featured on Channel 9 News. Prof. Rodney Sinclair, one of our Principal Investigators and a pioneering researcher, sat down with Channel 9 to discuss the study and the exciting science behind this program. Learn more about the ongoing study. Visit: https://headlinetrial.com/

Our HEADLINE™ Phase 1/2a clinical trial continues to progress in Australia under the guidance of renowned KOLs. Rodney Sinclair and Anthony Rossi MD, FAAD, FACMS break down the clinical trial program for ABS-201, an anti-PRLR antibody engineered using AI to tackle androgenetic alopecia (male/female pattern hair loss). ABS-201 represents a novel therapeutic approach targeting prolactin receptors to stimulate hair follicle regeneration and promote durable hair regrowth as demonstrated in in vivo studies. Recent translational human ex vivo scalp models demonstrated that ABS-201 effectively stimulates hair growth by regenerating the stem cell niche as well as promoting additional key growth modulators. We look forward to sharing interim data from our HEADLINE™ trial in the H2 2026. Learn more about the HEADLINE Trial: https://headlinetrial.com/

Soccer legend Landon Donovan, a FOX Sports analyst for their 2026 FIFA World Cup broadcast, recently took to Instagram to share his thoughts on our ABS-201 program and Headline Phase 1/2a clinical trial for hair loss. Earlier this year, Absci partnered with the U.S. sports icon to champion the patient voice in hair loss research. 📲 Learn more at HeadlineTrial.com